Filing Flows › Emergent BioSolutions (EBS) › Guidance & outlook
Emergent BioSolutions (EBS) guidance and outlook
Emergent BioSolutions (EBS) raised some and lowered other parts of its guidance on Nov 2, 2026: Revenue $600M–$645M for FY2026; Net income −$255M to −$225M for FY2026; Net income −$2.0M for FY2026; EBITDA −$2.0M for FY2026. Emergent BioSolutions' 10-Q filed Nov 3, 2026 makes 12 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $600M–$645M | lowered |
| Net income | FY2026 | −$255M to −$225M | lowered |
| Net income | FY2026 | −$2.0M | reaffirmed |
| EBITDA | FY2026 | −$2.0M | reaffirmed |
| Interest expense | FY2026 | $38.0M | lowered |
| Stock-based compensation | FY2026 | $19.0M | reaffirmed |
| Capital expenditures | FY2026 | $16.0M | lowered |
| Depreciation & amortization | FY2026 | $81.0M | lowered |
| Gross margin | FY2026 | 34%–36% | raised |
| Gross margin | FY2026 | 45%–47% | raised |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- In August 2026, the Company initiated an organizational restructuring plan (the “August 2026 Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth.
- During the preparation and review of the financial statements for the quarter ended June 30, 2026, the Company determined that changes in current and projected operating results, notably related to pricing and sales volumes for NARCAN ® , constituted a triggering event for the NARCAN ® asset group within the Commercial reporting unit.
- The Company estimated the fair value of the asset group using an income approach utilizing discounted projected future cash flows (level 3 fair value measurement).
- We expect continued variability in our quarterly financial results.
- We expect our R&D spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of R&D spending, the number of product candidates under development, the size, structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical…
- The Company is monitoring legislative developments, as well as additional guidance from countries that have enacted legislation.
- During the second quarter of 2026, we identified such indicators for the NARCAN ® asset group, including downward revisions to projected operating results and future cash flows, which resulted in an impairment assessment.
- If an impairment indicator is present, we evaluate recoverability of assets to be held-and-used by a comparison of the carrying value of the assets with future undiscounted net cash flows expected to be generated by the assets.
- If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset group, we estimate the fair value of the asset group to determine whether an impairment loss should be recognized.
- We anticipate that our future capital requirements will principally consist of funds required for:
- The timing and amount of any shares repurchased will be determined by the Company’s management based on its evaluation of market conditions and other factors, including the market price of the Company’s common shares, macroeconomic environment and other investment opportunities, consistent with applicable law.
- We expect to continue to fund our short-term and long-term anticipated operating expenses, capital expenditures and debt service requirements, any future debt repurchases and any future repurchases of our common stock from the following sources:
Emergent BioSolutions' latest quarter
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
Did Emergent BioSolutions raise or lower its guidance?
Emergent BioSolutions (EBS) raised some and lowered other parts of its guidance on Nov 2, 2026: Revenue $600M–$645M for FY2026; Net income −$255M to −$225M for FY2026; Net income −$2.0M for FY2026; EBITDA −$2.0M for FY2026.
What does Emergent BioSolutions expect?
In August 2026, the Company initiated an organizational restructuring plan (the “August 2026 Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. During the preparation and review of the financial statements for the quarter ended June 30, 2026, the Company determined that changes in current and projected operating results, notably related to pricing and sales volumes for NARCAN ® , constituted a triggering event for the NARCAN ® asset group within the Commercial reporting unit. The Company estimated
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.